Oncology ii

Oncology iii

Cardiovascular ii (CVD ii)

Cardiovascular iii (CVD iii)

Immuno-oncology

Mouse Exploratory

Cytokines

Mouse Cytokine

Michaëlsson E, Lund LH, Hage C, et al. Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF. (2023) JACC. Heart Failure, DOI: 10.1016/j.jchf.2023.03.002

Association between proteomic biomarkers and myocardial fibrosis measured by MRI: the multi-ethnic study of atherosclerosis. (Hooman et al, 2023) DOI:https://doi.org/10.1016/j.ebiom.2023.104490

Nurmohamed NS, Kraaijenhof JM, Mayr M, et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. (2023) European Heart Journal, DOI: 10.1093/eurheartj/ehad161

Proteomic Analysis of Mucosal and Systemic Responses to SARS-CoV-2 Antigen. (Martinson et al., 2023) DOI: 10.3390/vaccines11020334

Longitudinal proteomic profiling of the inflammatory response in dengue patients. (Garishah et al.,2023) DOI: 10.1371/journal.pntd.0011041

Optimizing a Diagnostic Model of Periodontitis by Using Targeted Proteomics. (Reckelkamm et al., 2023) DOI: 10.1021/acs.jproteome.3c00230

A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes. (Chowdhury et al., 2018)  DOI: 10.1038/s41586-018-0439-x

Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis. (Arias-de la Rosa I et al.,2023) 

DOI: 10.1016/j.ejim.2023.08.002

Elevation of IL-17 cytokines distinguishes Kawasaki disease from other pediatric inflammatory disorders. (Brodeur KE et al., 2023) 

DOI: 10.1002/art.42680

Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves’ ophthalmopathy in comparison to hyperthyroid patients without Graves’ ophthalmopathy. (Khamisi et al., 2023) Cytokine

DOI: 10.1016/j.cyto.2023.156269

Exploring proteomic plasma biomarkers in eosinophilic and neutrophilic asthma. (Kere M et al., 2022) 

DOI: 10.1111/cea.14229

Dobilas A, Åkesson A, Leandersson P, et al. A Multiplex Biomarker Assay Improves the Prediction of Survival in Epithelial Ovarian Cancer. (2023) Cancer Genomics & Proteomics, 

DOI: 10.21873/cgp.20380

Gyllensten U, Hedlund-Lindberg J, Svensson J, et al. Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancer. (2022) Cancers

DOI: 10.3390/cancers14071757

Mukama T, Fortner RT, Katzke V, et al. Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer. (2022) British Journal of Cancer

DOI: 10.1038/s41416-021-01697-z

Sabaa AA, Shen Q, Lennmyr EB, et al. Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls. (2022) New Biotechnoogy

DOI: 10.1016/j.nbt.2022.06.005

Urbiola-Salvador V, Miroszewska D, Jabłońska A, et al. Proteomics approaches to characterize the immune responses in cancer. (2022) Biochimica et Biophysica Acta Molecular Cell Research

DOI: 10.1016/j.bbamcr.2022.119266

Chen H, Qian J, Werner S, Cuk K, Knebel P and Brenner H. Development and validation of a panel of five proteins as blood biomarkers for early detection of colorectal cancer. (2017) Clinical Epidemiology

DOI: 10.2147/CLEP.S144171

Qian J, Tikk K, Werner S, Balavarca Y, Saadat M, Hechtner M and Brenner H. Biomarker discovery study of inflammatory proteins for colorectal cancer early detection demonstrated importance of screening setting validation.(2018) Journal of Clinical Epidemiology

DOI: 10.1016/j.jclinepi.2018.07.016

Tromp J, Boerman L, Sama I, Maass S, Maduro J, Hummel Y, Berger M, de Bock G, Gietema J, Berendsen A and van der Meer P. Long‐term survivors of early breast cancer treated with chemotherapy are characterized by a pro‐inflammatory biomarker profile compared to matched controls (2020) European Journal of Heart Failure

DOI: 10.1002/ejhf.1758